HOME ·

HENGRUI PHARMA

HENGRUI PHARMA (01276.HK): SHR-4685 Injection Obtains Clinical Trial Approval for Advanced Solid Tumours
Tags：
HENGRUI PHARMA01276.HKClinical Trial Application
2026-07-07
Hengrui Pharma (01276.HK): Enters Global Strategic Collaboration with Bristol Myers Squibb, Total Transaction Value Up to ~US$15.2 Billion
Tags：
HENGRUI PHARMA01276.HKStrategic Collaboration
2026-05-12
HENGRUI PHARMA (01276.HK): Five Innovative Drugs Obtain Clinical Trial Approvals, Targeting KRAS G12D and Other Indications
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): HRS-3005 Tablets Granted Clinical Trial Approval for B-Cell Malignancies
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 2.28 billion, YoY increase of 21.78%
Tags：
HENGRUI PHARMA01276.HKfinancials
2026-04-23
HENGRUI PHARMA(01276.HK): Receives Clinical Trial Approval for SHR-1049 Injection, Targeting Advanced Solid Tumors
Tags：
HENGRUI PHARMA01276.HK
2026-01-26